UroGen Pharma

UroGen is a pharmaceutical company focused on urological cancers. It has a portfolio of FDA-approved treatments leveraging its innovative RTGel technology, including Jelmyto and Zusduri. The company's pipeline is focused on innovative treatments for uro-oncology patients. UroGen is committed to conducting business with high ethical standards and has adopted a Comprehensive Compliance Program.

UroGen is a company committed to elevating options for people living with urological cancers. It has a portfolio of FDA-approved treatments leveraging its innovative RTGel technology, including Jelmyto and Zusduri. The company's pipeline is focused on innovative treatments for uro-oncology patients. UroGen has a Comprehensive Compliance Program and is led by President and CEO Liz Barrett.

• Jelmyto

  FDA-approved treatment leveraging RTGel technology

• Zusduri

  FDA-approved treatment leveraging RTGel technology

1. UroGen Pharma
2. UroGen Pharma | Corporate Responsibility
3. UroGen Pharma | What We Stand For
4. UroGen Pharma | Leadership
5. UroGen Pharma Ltd. (United States)